


# Advanced Nanomaterials for Biomedical Applications

Dr. Semih Çalamak



Dr. Çalamak will present an overview of his latest research publications in this seminar. The principal goal of his research is to apply innovative technologies to biomedical applications. His major research theme focuses on building nanoplasmonic platforms targeting broad applications in disposable point-of-care (POC) diagnostics and monitoring cancer biomarkers. Additionally, he focuses on creating regenerative bionanotextiles and new microfluidic technology platforms targeting broad applications in medicine.



Dr. Semih Çalamak is currently working as a Dr. Research Assistant at the Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy at Hacettepe University. In 2010, he completed double major undergraduate degrees in Biology and Chemistry at Gazi University. He obtained his M.Sc. and Ph.D. degrees in Nanotechnology and Nanomedicine in 2012 and 2018, respectively from Hacettepe University. During his doctoral studies, he was appointed as a visiting scientist at Stanford University, Canary Cancer Early Detection Center between Dec. 2014 and Dec. 2015. His research interests include the applications of nano/micro scale technologies and biomaterials in regenerative medicine, specifically focus on the nano/micro patterned biomaterials and their tissue engineering applications, 3D bioprinted tissue scaffolds and organ-on-a-chip systems. Dr. Çalamak has 17 published and 2 under review SCI indexed journal papers in esteemed publications such as PNAS, Advanced Science, Small, Drug Delivery and Material Science and Engineering C. His scientific work has been highlighted and recognized by international organizations including Fox News (USA). He has 23 international conference proceeding papers. Moreover, he secured his research findings, technological developments, and scientific discoveries with an U.S. patent. This patent has already been licensed by a company to produce commercial products in the United States (LevitasBio Inc.).